Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11

Udo zur Stadt1,*, Susanne Schmidt2,†, Brigitte Kasper3,†, Karin Beutel1, A. Sarper Diler4, Jan-Inge Henter5, Hartmut Kabisch1, Reinhard Schneppenheim1, Peter Nürnberg2,6, Gritta Janka1,* and Hans Christian Hennies2

1Department of Pediatric Hematology and Oncology, Children’s Hospital, University of Hamburg, Martinistr. 52, 20246 Hamburg, Germany, 2Gene Mapping Center and Department of Molecular Genetics, Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany, 3Department of Immunology and Cell Biology, Research Center Borstel, Borstel, Germany, 4University of Istanbul, Istanbul Medical Faculty Medical Biology Department and Bone Marrow Bank, Turkey, 5Department of Woman and Child Health, Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden and 6Institute of Medical Genetics, Charité, University Medicine of Berlin, Berlin, Germany

Received January 4, 2005; Revised and Accepted January 27, 2005

Familial hemophagocytic lymphohistiocytosis (FHL) is a rare autosomal recessive disorder characterized by hyperactive phagocytes and defects in natural killer cell function. It has been shown previously that mutations in the perforin 1 gene (PRF1) and in UNC13D are associated with FHL2 and FHL3, respectively, indicating genetic heterogeneity. We performed genome-wide homozygosity mapping in a large consanguineous Kurdish kindred with five children affected with FHL. Linkage to a 10 cM region on chromosome 6q24 between D6S1569 and D6S960 defined a novel FHL locus. By screening positional candidate genes, we identified a homozygous deletion of 5 bp in the syntaxin 11 gene (STX11) in this family. We could demonstrate that syntaxin 11 protein was absent in the mononuclear cell fraction of patients with the homozygous 5 bp deletion. In addition to this family, we found homozygous mutations in STX11 in five consanguineous Turkish/Kurdish FHL kindreds including two families with the 5 bp deletion, one family with a large 19.2 kb genomic deletion spanning the entire coding region of STX11 (exon 2) and two families with a nonsense mutation that leads to a premature stop codon in the C-terminal end of the protein. As both STX11 and UNC13D are involved in vesicle trafficking and membrane fusion, we conclude that, besides mutations in perforin 1, defects in the endocytotic or the exocytotic pathway may be a common mechanism in FHL.

INTRODUCTION

Familial hemophagocytic lymphohistiocytosis (FHL) is a genetically heterogeneous disorder typically first manifesting in early childhood with a rapidly fatal outcome if untreated (1). At diagnosis, patients present with a hyperinflammatory syndrome characterized by persistent fever, hepatosplenomegaly, cytopenia and, less frequently, central nervous system involvement. Common laboratory findings include low levels of fibrinogen and high concentrations of triglycerides, ferritin and the alpha-chain of the soluble interleukin 2 receptor (sCD25) secreted by activated T-cells. Defective natural killer (NK) cell activity is a hallmark of the disease (2). Hemophagocytosis in bone marrow, cerebrospinal fluid or lymph nodes by activated histiocytes may be absent initially but can be observed later in many of the cases. Chemoinmunotherapy based on corticosteroids, epipodophyllotoxins, cyclosporin A and antithymocyte globulins results in control of the disease in the majority of patients; however, remission is rarely sustained (3,4). Most patients suffer an early death unless treated by hematopoietic stem cell transplantation (HSCT), which is the only curative approach so far (5).

Linkage analysis in FHL patients has identified a genomic region with a defect in a still unknown gene on chromosome...
9q21 (FHL1; MIM 603552) (6), and a defect in the perforin 1 gene (PRF1) on chromosome 10q21 (FHL2; MIM 603553) (7,8). In FHL2, perforin mutations lead to significant reduction or complete absence of protein synthesis resulting in a defective cytolytic activity of T-cells and NK cells (9) [reviewed by Arico et al. (10)]. The incidence and type of PRF1 mutations vary in different ethnic groups (11–15). Very recently, FHL3 was identified on chromosome 17q25 with mutations in the gene UNCI3D (16). The gene product of UNCI3D, hMunc13-4, is a member of a protein family involved in vesicle priming, which prepares cytolytic granules at the plasma membrane for vesicle membrane fusion. Lymphocytes of FHL patients with UNCI3D mutations were shown to lack the ability to deliver cytotoxic substances like perforin or granzyme B to the target cells. Both proteins, perforin and granzyme B, are directly involved in the cytotoxic response of the immune system to exogenous or endogenous pathogens (17). It can be assumed that defects in other genes involved in the release of cytotoxic proteins could also lead to the clinical picture of FHL. In fact, two other related disorders characterized by hemophagocytosis and immune defects are the Chédiak–Higashi Syndrome (CHS) and the Griscelli-Syndrome (GS2) with defects in the genes CHS1 and RAB27A, respectively (18,19). Patients with these disorders have defective NK and/or T-cell cytotoxicity and, besides the overall secretion deficiency in immune cells, defects in the transport of pigment proteins that result in a partial albinism, not seen in the classical FHL forms (20). In all types of genetically based hemophagocytosis syndromes, the immune defect leads to the same severe clinical picture as in FHL. As all primary forms of FHL should rapidly undergo HSCT, early identification of the underlying genetic defect is crucial for patients without family history.

In the present study, we excluded mutations in PRF1 by genomic sequencing of the entire coding region, and performed a genome-wide homozygosity analysis in a large consanguineous FHL kindred of Kurdish descent. Linkage analysis led to identification of a novel FHL locus on chromosome 6q24, designated FHL4. By analyzing several genes residing in this region, we identified a homozygous 5 bp deletion in STX11 in all affected patients of this family. We could show that the 5 bp deletion, resulting in a premature stop codon, leads to abrogation of syntaxin 11 protein synthesis. We identified three different mutations in STX11 in a total of 10 patients from six different families with FHL, all of them with a common ethnic background.

RESULTS
Identification of FHL4 by linkage and homozygosity analysis
A genome-wide homozygosity analysis was performed with 19 members of the large consanguineous FHL family of Kurdish origin described earlier (family 1). By analyzing 380 markers, all known loci for FHL, namely FHL1, FHL2 (PRF1) and FHL3 (UNCI3D) were clearly excluded. We obtained a maximum two-point LOD score of 4.89 at Θ = 0.00 to D6S311 on chromosome 6q24 representing the only region with an LOD score significant for linkage (Table 1). We confirmed the localization by construction of likely haplotypes and demonstrated homozygosity in a 10 cM interval between D6S1569 and D6S960 in all affected individuals, and a heterozygous mutant haplotype in all obligate carriers (Fig. 1). A maximum multi-point LOD score of 4.94 was obtained between D6S1649 and D6S311. We have designed this novel locus for FHL FHL4.

Detection of homozygous mutations in STX11
The candidate genomic region is 11 Mb in length and harbors more than 50 different known or predicted genes (Fig. 2A). Among other candidates, we analyzed the gene encoding syntaxin 11 (STX11) as syntaxins are known for their function in vesicle transport. The STX11 gene consists of two exons and covers a genomic interval of 37 kb (Fig. 2B), of which exon 2 contains all of the coding sequence. We identified a homozygous deletion of two plus three nucleotides, c.369_370delAG and c.374_376delCGC, in exon 2 of STX11 (Fig. 2C). Both deletions completely cosegregated in the pedigree. The total deletion of five basepairs leads to a frameshift and a premature termination codon after 59 altered residues (Fig 2D). The homozygous mutation, Val124fsX60, was found in all affected children of the family, the heterozygous mutation was present in the obligate carriers. Neither the complete mutation nor the 2 bp or the 3 bp deletion alone was identified in samples from more than 200 control subjects of Kurdish or Turkish descent. Subsequently, additional FHL patients of Turkish or Kurdish

Table 1. Two-point LOD scores for each analyzed marker from the FHL4 interval and FHL in the large, consanguineous Kurdish family used for the genome-wide scan

<table>
<thead>
<tr>
<th>Marker</th>
<th>Recombination fraction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.000</td>
</tr>
<tr>
<td>D6S1009</td>
<td>−1.873</td>
</tr>
<tr>
<td>D6S1569</td>
<td>−∞</td>
</tr>
<tr>
<td>D6S308</td>
<td>1.516</td>
</tr>
<tr>
<td>D6S971</td>
<td>0.902</td>
</tr>
<tr>
<td>D6S1649</td>
<td>3.038</td>
</tr>
<tr>
<td>GATA184A08</td>
<td>3.663</td>
</tr>
<tr>
<td>D6S960</td>
<td>−∞</td>
</tr>
<tr>
<td>D6S2436</td>
<td>−∞</td>
</tr>
</tbody>
</table>
descent without PRF1 mutations were analyzed for mutations in STX11. In two patients from different families of Kurdish origin (families 2 and 3, respectively), the homozygous mutation Val124fsX60 was also present (Table 2).

The analysis of marker loci around STX11, namely GATA129G07, D6S1569, D6S308, D6S971, D6S1649, GATA184A08 and D6S311, revealed the same mutant haplotypes in the patients from families 1, 2 and 3 in a 5.9 cM interval between D6S1569 and D6S311. As these families had the same ethnic background and originated from the north eastern part of Turkey, mutation Val124fsX60 probably had a single, common origin.

In family 4, mutations in PRF1 or UNC13D were excluded by direct sequencing of the entire coding regions. Amplification of genomic DNA from the patient yielded no product for exon 2 of STX11. Normal amplification was observed with DNA from other family members (father, mother and one sister; data not shown). To characterize a possible homozygous deletion within STX11, we established a semi-quantitative DHPLC assay to detect heterozygosity in obligate carriers. In a first approach, duplex PCR was performed with an interchromosomal control (exon 3 of VWF on chromosome 12) and fragment 1 of exon 2 (Ex2-1) of STX11. To detect differences in the amount of PCR product between individuals, reactions were stopped in the logarithmic phase after 27 cycles. DHPLC analysis revealed no STX11 PCR product in the sample from the patient and C25% DNA amount in parents when compared with controls (Fig. 3A). Amplification of the internal control was at comparable levels in all four samples.

Several fragments, each 300–400 bp in length, were analyzed in order to identify the deletion breakpoints. They covered a total of 37.6 kb genomic DNA from exon 2 and adjacent regions (Fig. 3B). Whereas all reactions from a control DNA resulted in expected products, reactions c–f from DNA of the patient failed, indicating a homozygous genomic deletion in this region (Fig. 3B, upper panel). PCR with primers flanking this interval and subsequent sequence analysis identified a breakpoint spanning fragment, which revealed a deletion of 19 189 bp including part of intron 1 and the entire coding region of STX11. The breakpoint was located between nucleotide 25560 and nucleotide 44750 of

Figure 1. Pedigree of the large Kurdish FHL family used for the mapping study and construction of haplotypes in the FHL4 region on chromosome 6. The filled box denotes the mutant haplotype completely cosegregating with the FHL4 mutation. Obligatory recombination events and lack of homozygosity, respectively, define the critical interval between D6S1569 and D6S960.
DISCUSSION

FHL is a severe disease of uncontrolled inflammation characterized by fever, hepatosplenomegaly, cytopenia, hemophagocytosis and characteristic laboratory values. Diagnostic guidelines were published by the Histioctye Society in 1991 (24), and revised criteria were summarized in 2004 by Janka and Schneider (2). The uncontrolled activation of immune cells is thought to occur because of an incomplete eradication of infectious organisms or an inadequate response to endogenous factors like tissue damage, autoantigens or other stimuli. Nearly all FHL patients exhibit a complete deficiency of NK cell activity as measured in a standard 4 h chromium release assay against K562 cells (25).

Two different molecular defects have been identified earlier, indicating genetic heterogeneity. Mutations in PRF1 (FHL2) and UNC13D (FHL3) disrupt the ability of cytotoxic cells to kill their targets. Whereas mutations in PRF1 lead to reduced amounts or absent perforin 1 in cytotoxic granules, defects in UNC13D inhibit the priming step of these granules prior to vesicle membrane fusion.

In addition to mutations in PRF1 (FHL2) and UNC13D (FHL3), we here present a novel genetic defect in FHL, in STX11 on chromosome 6q24, which we identified after homozygosity mapping in a large Kurdish FHL family with altogether six affected individuals. The homozygous mutation, Val124fsX60, found in all five investigated patients from this family was predicted to result in a premature termination codon...
Table 2. Characteristics of patients reported with mutations in syntaxin 11

<table>
<thead>
<tr>
<th>Family (patient)</th>
<th>Mutation in STX11</th>
<th>Deduced peptide change</th>
<th>Sex</th>
<th>Age at onset (months)</th>
<th>Age at HSCT(^d) (months)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (IV:9)(^b)</td>
<td>c.369_370delAG/c.374_376delCGC</td>
<td>Val124fsX60</td>
<td>M</td>
<td>12</td>
<td>125</td>
<td>Alive (&gt;10 years)</td>
</tr>
<tr>
<td>1 (IV:9)(^b)</td>
<td>c.369_370delAG/c.374_376delCGC</td>
<td>Val124fsX60</td>
<td>M</td>
<td>39</td>
<td>113</td>
<td>Alive (&gt;10 years)</td>
</tr>
<tr>
<td>1 (V:1)</td>
<td>c.369_370delAG/c.374_376delCGC</td>
<td>Val124fsX60</td>
<td>M</td>
<td>24</td>
<td>43</td>
<td>Alive (&gt;1 year)</td>
</tr>
<tr>
<td>2 (V:2)</td>
<td>c.369_370delAG/c.374_376delCGC</td>
<td>Val124fsX60</td>
<td>F</td>
<td>5</td>
<td>16</td>
<td>Dead (graft rejection)</td>
</tr>
<tr>
<td>3 (V:3)</td>
<td>c.369_370delAG/c.374_376delCGC</td>
<td>Val124fsX60</td>
<td>F</td>
<td>17</td>
<td>27</td>
<td>Dead (&gt;1.5 years)</td>
</tr>
<tr>
<td>4</td>
<td>AL135917:g.25561_44749del</td>
<td>deletion</td>
<td>F</td>
<td>7</td>
<td>16</td>
<td>Alive (~2 months)</td>
</tr>
<tr>
<td>5</td>
<td>c.802C→T</td>
<td>Gln268X</td>
<td>M</td>
<td>16</td>
<td>Not transplanted</td>
<td>Alive</td>
</tr>
<tr>
<td>6</td>
<td>c.802C→T</td>
<td>Gln268X</td>
<td>F</td>
<td>1.5</td>
<td>Not transplanted</td>
<td>Alive</td>
</tr>
</tbody>
</table>

\(^a\)Numbering according to Figure 1.  
\(^b\)First described by Henter et al. (36).  
\(^c\)V:2 and V:3 were monozygotic twins.  
\(^d\)HSCT, hematopoietic stem cell transplantation.  
\(^e\)TRM, transplantation related mortality.

codon leading to complete loss of syntaxin 11. We further detected the 5 bp deletion, a 19 kb deletion including exon 2 or a nonsense mutation in five additional families with FHL, all of them with the same ethnic background.

Syntaxin 11 is a member of soluble N-ethylmaleimide sensitive factor attachment protein receptors present on target membranes (t-SNAREs) (26,27). In contrast to other syntaxins, it harbors a short cystein-rich C-terminal tail instead of a hydrophobic membrane anchor that serves as a putative palmitoylation site (21,28). Despite the lack of this membrane anchor, syntaxin 11 is retained in membrane protein fractions solubilized by Triton X-100 treatment (23). As expected from the SNARE hypothesis of regulated intracellular vesicle transport, which specified the complex organization within different intracellular membrane fusion processes (29), the non-neuronal SNAP25 homolog SNAP23 was clearly identified as one of the binding partners in vivo (23). A SNARE complex harbors a four-helix bundle including a vesicle-associated v-SNARE (synaptobrevin/VAMP), a t-SNARE (syntaxin) and two molecules of either SNAP25 involved in neuronal complexes or SNAP23 in complexes associated with fusions in non-neuronal cell types (26). All syntaxin family members harbor an N-terminal H\(_{ABC}\) domain that regulates SNARE complex formation (30).

In FHL3, the priming step at the immunological synapse during exocytosis of cytotoxic vesicles is abrogated because of mutations in \(UNC13D\) as recently described by Feldmann et al. (16). It is unlikely that syntaxin 11 is involved in these steps during exocytosis because of the different intracellular localization. Confocal immunofluorescence microscopy analysis showed a strong association of syntaxin 11 with the intermediate compartment, a region between late endosomal areas and the trans-Golgi network suggesting a regulatory role in cycling between these two compartments. Syntaxin 11 may actively be involved in the transport of yet unknown vesicles from intracellular regions to the cell surface rather than being directly involved in exocytotic processes as other homologues such as syntaxins 1–4.

As we do not know the exact role of syntaxin 11 in the intracellular vesicle transport of the phagocytic system, a clear functional link to the characteristic features of the disease is still elusive. The genes known previously to underlie FHL, \(PRF1\) and \(UNC13D\), are directly associated with the effector cells, cytotoxic T, or NK-cells. The \(PRF1\)/granzyme dependent cytotoxic pathway is essential for the elimination of target cells transformed or infected with viral proteins (31). On the other hand, NK cells are stimulated by cell-to-cell interactions with DCs. This direct DC to NK cell contact seems to have an impact on the activation of the cytolytic activity of NK cells and their IFN-\(\gamma\) production (32). Thus, a reduced or absent NK cell activity may be caused not only by mutations in \(PRF1\) or \(UNC13D\) but also indirectly by an incomplete activation of NK cells by DCs (33). Future studies have be initiated to investigate these complex interactions.

Clinically, the age at onset of the disease and the time between diagnosis and time point of transplantation in the seven patients from three different families with homozygous mutation Val124fsX60 varied markedly (Table 2). The patient from family 4 with a complete deletion of the \(STX11\) coding region had the first signs of FHL at the age of 33 months (Table 2). This is strikingly different from our findings regarding the most common \(PRF1\) mutation detected in patients who originated from Turkey. All patients with a homozygous mutation 1122G→A (Trp374X) had a very early onset of the disease between 1 and 3 months of age (34). These Trp374X patients should also undergo HSCT as soon as possible to avoid an early death. Both types of mutations result in a premature stop codon in either \(PRF1\) or \(STX11\), and both groups of patients were otherwise clinically very similar. Insufficient defense against a pathogen may result more efficiently and more rapidly in the typical signs of FHL in perforin 1-deficient patients than in those with a defect in \(STX11\), because syntaxin 11 is not directly involved in the ‘killing’ machinery. Nevertheless, the described patient groups are too small to make a statistically significant conclusion. The identification of \(STX11\) as a novel gene involved in the development of FHL will provide new insights into the mechanisms of the disease and will also further facilitate...
genetic counseling and prenatal diagnosis (35) in affected families.

MATERIALS AND METHODS

Families

All patients specified in this study are children of Kurdish origin with consanguineous parents. They all fulfilled the diagnostic criteria for FHL including decreased NK cell activity in the standard 4 h 51Cr release assay (24). Patients’ characteristics are given in Table 2 and the index family analyzed for linkage (family 1) is described in more detail subsequently.

In family 1, FHL was first diagnosed in three members of the family, two of whom were included in the study described here (IV:8, IV:9 in Fig. 1). The age at onset of the disease in the three brothers was 3, 12 and 39 months, respectively. The oldest brother died shortly after diagnosis, and samples were not available for further studies. The other two underwent HSCT after several relapses, and they are both alive. Clinical data from these patients have been described previously (36).

The first signs of FHL in one of the monozygotic female twins (V:2) occurred at 5 months of age. Haploidentical HSCT with the father as a donor was performed at the age of 15 months. After primary graft failure and no engraftment of the autologous back-up, the child died. At the age of 25 months, the brother (V:1) was referred to the hospital with a history of fever and diarrhea. In the other twin sister (V:3), onset of disease did not occur until the age of 15 months. Both children received HSCT from unrelated donor and are presently doing well.

Samples

For linkage analysis, DNA was extracted from peripheral whole blood. In case of patients who had undergone HSCT, we prepared DNA from mouth wash material and from fibroblast cultures. Once the gene had been identified, additional patients with FHL from Turkey were investigated. We obtained written informed consent from all patients and family members before the study was performed.

Homozygosity mapping and linkage analysis

A whole-genome scan was performed with 380 microsatellite markers (37), with an average distance of 11 cM. Markers were amplified in singleplex reactions in a final reaction volume of 10 μl containing 6 ng of genomic DNA. DNA amplification was carried out in PTC-225 thermal cyclers (MJ Research). Products were then pooled, and semi-automated genotyping was performed with MegaBACE-1000 analysis systems (Amersham Biosciences). Data were analyzed with Genetic Profiler software, version 1.5. Two-point LOD score calculations were performed with the program package LINKAGE version 5.2 (38) using an autosomal recessive model with full penetrance. Haplotypes were constructed either manually or with the program SIMWALK (39). SIMWALK was also used for the calculation of multipoint LOD scores, assuming equal allele frequencies.

Mutation analysis

The genomic structure of STX11 was determined by alignment of the cDNA sequence (NM_003764) with the appropriate sequence of a genomic chromosome 6 contig (AL135917). Primers used for amplification of the coding exon were as follows: Ex2F (5’-ACTTATTGCCACACCGAGGAATAC) and Ex2R (5’-GTTGCGTTCTGACAAGGTAGAG) with two internal sequencing primers, Ex2-2F and Ex2-3F. For subsequent analysis of additional samples and for DHPLC...
analysis of control samples, exon 2 of STX11 was divided into three PCR fragments using the following primer pairs:

Ex2-1F (5’-ACTTTGCCCCACCCAGGAAATAAC) and Ex2-1R (5’-TTGCGATGGAGTCTCAGGC); Ex2-2F (5’-AGAACCCGCAGCTTCACGTCC) and Ex2-2R (5’-TGCCGCTCTCGATCTCGGAG); Ex2-3F (5’-ACCAGATCGAGACATTTGGAG) and Ex2-3R (5’-AGAGCTCCCCGTGTGGGC)

**DHPLC analysis**

As control, for the presence or absence of the 5 bp deletion in STX11 230 samples of healthy blood donors from Turkey were analyzed. General DHPLC conditions were described elsewhere (40). DHPLC-based mutation analysis in fragments 1–3 of exon 2 (Ex2-2) was performed at 66 and 68°C column oven temperature. DHPLC-based semi-quantitative PCR analysis was performed at a column oven temperature of 50°C. DHPLC was performed on a WAVE system (Transgenicom, Crewe, UK).

**Antibodies and inhibitors**

Polyclonal rabbit antiserum raised against human SNAP23 was purchased from Novus Biochemicals (Littleton, CO, USA), and monoclonal antibody directed against amino acids 12–41 of human syntaxin 11 (clone 32) was from BD Transduction Laboratories (Heidelberg, Germany). Alexa680-conjugated goat anti-mouse IgG was obtained from MoBiTec (Göttingen, Germany) and IRDye800-conjugated goat anti-rabbit IgG was from BIOTREN (Köln, Germany). Complete and Pefabloc SC were obtained from Roche (Mannheim, Germany) and okadaic acid from Alexis (Grünbek, Germany).

**Preparation of mononuclear cells**

MNC were routinely isolated from ethylenediaminetetraacetic acid (EDTA) blood of healthy controls and patients, respectively, by dextran sedimentation (Plasmasteril; Fresenius, Oberursel, Germany) followed by Ficoll-Hypaque (Pharmacia; Uppsala, Sweden) density centrifugation as described elsewhere (41). MNC were collected by rapid centrifugation. Cells were lysed in hypotonic lysis buffer (42 mM KCl, 10 mM HEPES, pH 7.4, 5 mM MgCl2) supplemented with inhibitors (2 mM sodium ortho-vanadate, 2 mM NaF, 500 mM okadaic acid, 4 mM Pefabloc, and 1x Complete). Lysates were centrifuged at 250g for 10 min at 4°C to remove nuclei and intact cells. The supernatant was cleared by centrifugation at 150,000 g for 10 min at 4°C to separate the cytoplasm from the membrane fraction. The membrane fraction was then lysed for 30 min on ice in the same volume of 1% Triton X-100 in TNE buffer (10 mM Tris–HCl pH 7.5, 150 mM NaCl, 5 mM EDTA) supplemented with inhibitors. Lysates were centrifuged at 150,000 g for 30 min at 4°C to remove Triton-insoluble material, and protein concentrations were determined in the supernatant by the method of Bradford (42), using BSA as a standard (Biorad, München, Germany). For western blotting, 50 μg protein were diluted in 3-fold concentrated sample buffer, and the samples were boiled for 5 min prior to electrophoresis.

**Western blot analysis**

Proteins derived from cell lysates were separated by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) (43) using a 10% polyacrylamide gel and blotted onto polyvinylidene fluoride (PVDF) membranes (Biorad, Munich, Germany) with a tank-blot transfer unit (Transphor II; Amersham Pharmacia Biotech, Freiburg, Germany). Immunodetection was performed as described in detail elsewhere (44) with some modifications. Briefly, membranes were blocked in Roti-Immunoblock (Roth, Karlsruhe, Germany), incubated with the respective primary antibodies and Alexa680-conjugated goat anti-mouse IgG or IRDye800-conjugated goat anti-rabbit IgG secondary antibodies according to the manufacturer’s recommendations. Bands were visualized by Odyssey infrared imaging system (LICOR, Bad Homburg, Germany).

**Electronic Database Information**


**Acknowledgements**

We are grateful to the families involved for their participation in this research project. We thank the following physicians for their generous cooperation in this study: P. Gutjahr (Mainz, Germany); A. Kulozik (Heidelberg, Germany); Th. Kühne (Basel, Switzerland); T. Celkan (Istanbul, Turkey); A. Gulen (Izmir, Turkey). We thank F. Oyen, B. Weber and N. Wittstruck for excellent technical assistance. This work was supported by grants in aid from the ‘Fördergemeinschaft Kinderkrebszentrum Hamburg e.V.’ and the National Genome Research Network.

**References**


20. Cytosolic proteins from neutrophil granulocytes: a comparison between patients with severe chronic neutropenia and healthy donors. Electrophoresis, 18, 142–149.

